Splenectomy Following JAK1/JAK2 Inhibitor Therapy in Patients With Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation
ConclusionSplenectomy before alloHSCT might be a promising option in patients who failed to achieve significant spleen response after ruxolitinib therapy.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Hematology | Splenectomy | Stem Cell Therapy | Stem Cells | Study | Thrombosis | Transplants